AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Quantum Genomics Share Issue/Capital Change 2019

Feb 15, 2019

1617_dva_2019-02-15_0ae75e43-7c11-4447-a6c8-f052a520b5a0.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Information relating to the total number of voting rights forming the share capital

Article L. 238-8-II of the French commercial Code and article 223-16 of the AMF (French Financial Markets Authority) general regulation

Date	Total number of shares forming the share capital	Total number of voting rights
31/01/2019	16,294,349(1)	Total number of theoretical voting rights(2) :	18,079,115
		Total number of voting rights that may be exercised(3) :	18,020,110

(1) of which 4,947,000 new shares issued since April 2018 under the equity line financing agreement concluded with Kepler Cheuvreux in March 2018 (see press release dated 03/05/2018).
(2) after taking into account the shares with double voting rights and the treasury shares.
(3) after deducting the shares without voting right (treasury shares).

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).

Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).

For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn

Contact information

Quantum Genomics
Jean-Philippe Milon	Marc Karako
CEO	CFO - Investor Relations
+33 (0)1 85 34 77 70 [email protected]	+33 (0)1 85 34 77 70 [email protected]
So Bang (Europe)
Nathalie Boumendil	Samuel Beaupain
Financial Communications	Media Relations and Scientific Communications
+33 (0)6 85 82 41 95 [email protected]	+33 (0)6 88 48 48 02 [email protected]
LifeSci (USA)
Dan Ferry	Michael Tattory
Financial Communications	Media Relations and Scientific Communications
+1 (617) 535-7746 [email protected]	+1 (646) 751-4362 [email protected]